Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
Castle Biosciences presented data at EADV 2026 showing DecisionDx-Melanoma's ability to predict low SLN positivity and high recurrence risk in melanoma patients. The study involved 2,799 patients across 29 U.S. centers, with low-risk patients avoiding SLNB showing 99.6% five-year RFS. The test also stratified recurrence risk in early-stage, transected melanomas, supporting tailored surveillance. Castle Biosciences is a Nasdaq-listed company (CSTL).
How this was made
The 30-second read
Why it matters
The presented study is the largest prospective multicenter validation to date, potentially strengthening the test's clinical credibility and market positioning.
Market read
First public disclosure of robust prospective data could influence CSTL's valuation and the broader molecular diagnostics sector.
What to watch
Reimbursement policies, competition from other melanoma biomarkers, and the need for longer-term outcome data.
Background
Castle Biosciences (Nasdaq:CSTL) is a diagnostics company focused on dermatology and gastroenterology. The DecisionDx-Melanoma test uses a 31‑gene expression profile to stratify melanoma patients.
Ticker impact
Castle Biosciences presented new prospective study data on its DecisionDx-Melanoma test, showing low-risk patients have <5% SLN positivity and 99.6% five-year RFS, a first public disclosure of these results.
potential modest upside as investors price in expanded market opportunity
First-time release of large prospective study results for a commercial diagnostic test; market may react positively but magnitude likely limited.
Market effects
May boost confidence in gene expression profiling diagnostics within oncology, potentially benefiting peers in molecular diagnostics.
Primarily U.S. market, limited regional effect.
Limited global impact; relevance confined to investors tracking precision oncology diagnostics.
Counterpoint
Data may not translate into commercial uptake if reimbursement or payer acceptance lags.
Key entities
- CompanyCastle Biosciences
Developer of DecisionDx-Melanoma diagnostic test.
- ProductDecisionDx-Melanoma
31‑gene expression profile test for melanoma risk stratification.
